Swerdlow S, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, Thiele, J, Arber, DA, Hasserjian, RP, Le Beau, MM, Orazi, A, and Siebert, R (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, France, pp

Campo E, Jaffe ES, Cook JR et al (2022) The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140:1229–1253. https://doi.org/10.1182/blood.2022015851

Article  CAS  PubMed  Google Scholar 

Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours Lymphoid Neoplasms. Leukemia 36:1720–1748

Article  PubMed  PubMed Central  Google Scholar 

Lai R, Medeiros LJ, Dabbagh L et al (2000) Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma. Mod Pathol 13:223–228. https://doi.org/10.1038/modpathol.3880041

Article  CAS  PubMed  Google Scholar 

Oliveira JL, Grogg KL, Macon WR et al (2012) Clinicopathologic features of B-cell lineage neoplasms with aberrant expression of CD3: a study of 21 cases. Am J Surg Pathol 36:1364–1370. https://doi.org/10.1097/PAS.0b013e31825e63a9

Article  PubMed  Google Scholar 

Durani U, Ansell SM (2021) CD5+ diffuse large B-cell lymphoma: a narrative review. Leuk Lymphoma 62:3078–3086. https://doi.org/10.1080/10428194.2021.1953010

Article  CAS  PubMed  Google Scholar 

Hu B, Nastoupil LJ, Loghavi S et al (2020) De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma 61:328–336. https://doi.org/10.1080/10428194.2019.1663418

Article  CAS  PubMed  Google Scholar 

Tzankov A, Leu N, Muenst S et al (2015) Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. J Hematol Oncol 8:70. https://doi.org/10.1186/s13045-015-0168-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsiao SC, Cortada IR, Colomo L et al (2012) SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology 61:685–693. https://doi.org/10.1111/j.1365-2559.2012.04260.x

Article  PubMed  Google Scholar 

Cheng J, Hashem MA, Barabe F et al (2021) CCND1 genomic rearrangement as a secondary event in high grade B-cell lymphoma. Hemasphere 5:e505. https://doi.org/10.1097/HS9.0000000000000505

Article  PubMed  Google Scholar 

Ok CY, Xu-Monette ZY, Tzankov A et al (2014) Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer 120:1818–1829. https://doi.org/10.1002/cncr.28664

Article  CAS  PubMed  Google Scholar 

Koduru PR, Chen W, Garcia R et al (2015) Acquisition of a t(11;14)(q13;q32) in clonal evolution in a follicular lymphoma with a t(14;18)(q32;q21) and t(3;22)(q27;q11.2). Cancer Genet 208:303–309. https://doi.org/10.1016/j.cancergen.2015.03.007

Article  CAS  PubMed  Google Scholar 

Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121:2253–2263. https://doi.org/10.1182/blood-2012-06-435842

Article  CAS  PubMed  Google Scholar 

Staiger AM, Ziepert M, Horn H et al (2017) Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin’s lymphoma study group. J Clin Oncol 35:2515–2526. https://doi.org/10.1200/JCO.2016.70.3660

Article  CAS  PubMed  Google Scholar 

Meriranta L, Pasanen A, Alkodsi A et al (2020) Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma. Blood Adv 4:3742–3753. https://doi.org/10.1182/bloodadvances.2020001727

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511. https://doi.org/10.1038/35000501

Article  CAS  PubMed  Google Scholar 

Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282. https://doi.org/10.1182/blood-2003-05-1545

Article  CAS  PubMed  Google Scholar 

Leonard JP, Kolibaba KS, Reeves JA et al (2017) Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol 35:3538–3546. https://doi.org/10.1200/JCO.2017.73.2784

Article  CAS  PubMed  Google Scholar 

Nowakowski GS, Chiappella A, Gascoyne RD et al (2021) ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 39:1317–1328. https://doi.org/10.1200/JCO.20.01366

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frauenfeld L, Castrejon-de-Anta N, Ramis-Zaldivar JE et al (2022) Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. Blood Adv 6:2361–2372. https://doi.org/10.1182/bloodadvances.2021006034

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colomo L, Loong F, Rives S et al (2004) Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 28:736–747. https://doi.org/10.1097/01.pas.0000126781.87158.e3

Article  PubMed  Google Scholar 

Meyer PN, Fu K, Greiner TC et al (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29:200–207. https://doi.org/10.1200/JCO.2010.30.0368

Article  PubMed  Google Scholar 

Choi WW, Weisenburger DD, Greiner TC et al (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15:5494–5502. https://doi.org/10.1158/1078-0432.CCR-09-0113

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed S, Glover P, Taylor J et al (2021) Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance. Br J Haematol 192:599–604. https://doi.org/10.1111/bjh.17246

Article  CAS  PubMed  Google Scholar 

Scott DW, Wright GW, Williams PM et al (2014) Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123:1214–1217. https://doi.org/10.1182/blood-2013-11-536433

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilson WH, Wright GW, Huang DW et al (2021) Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 39(1643–1653):e1643. https://doi.org/10.1016/j.ccell.2021.10.006

Article  CAS  Google Scholar 

Wright GW, Huang DW, Phelan JD et al (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37(551–568):e514. https://doi.org/10.1016/j.ccell.2020.03.015

Article  CAS  Google Scholar 

Chapuy B, Stewart C, Dunford AJ et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679–690. https://doi.org/10.1038/s41591-018-0016-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmitz R, Wright GW, Huang DW et al (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378:1396–1407. https://doi.org/10.1056/NEJMoa1801445

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lacy SE, Barrans SL, Beer PA et al (2020) Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood 135:1759–1771. https://doi.org/10.1182/blood.2019003535

Article  CAS  PubMed  PubMed Central  Google Scholar 

Autio M, Leivonen SK, Bruck O et al (2022) Clinical impact of immune cells and their spatial interactions in diffuse large B-cell lymphoma microenvironment. Clin Cancer Res 28:781–792. https://doi.org/10.1158/1078-0432.CCR-21-3140

Article  CAS  PubMed  Google Scholar 

Steen CB, Luca BA, Esfahani MS et al (2021) The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell 39(1422–1437):e1410. https://doi.org/10.1016/j.ccell.2021.08.011

Article  CAS  Google Scholar 

Godfrey J, Tumuluru S, Bao R et al (2019) PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood 133:2279–2290. https://doi.org/10.1182/blood-2018-10-879015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scott DW, King RL, Staiger AM et al (2018) High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131:2060–2064. https://doi.org/10.1182/blood-2017-12-820605

Article  CAS  PubMed  PubMed Central  Google Scholar 

King RL, Hsi ED, Chan WC et al (2022) Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma. Virchows Arch. https://doi.org/10.1007/s00428-022-03404-6

A